Balyasny Asset Management L.P. Takes $2.12 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Balyasny Asset Management L.P. purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 15,419 shares of the biotechnology company's stock, valued at approximately $2,123,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth approximately $30,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. grew its holdings in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares in the last quarter. Quarry LP bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $96,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 664 shares during the period.

Ascendis Pharma A/S Stock Up 0.0%

Shares of ASND stock traded up $0.06 during trading on Friday, reaching $157.60. The company's stock had a trading volume of 502,233 shares, compared to its average volume of 494,419. The company has a market cap of $9.61 billion, a price-to-earnings ratio of -22.20 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The business has a fifty day moving average price of $156.91 and a 200-day moving average price of $142.15.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analysts' expectations of $98.56 million. Research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on ASND. Wedbush raised their target price on Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Morgan Stanley upgraded Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $180.00 to $250.00 in a report on Monday, May 5th. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $216.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.